INSP Inspire Medical Systems (INSP) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001609550
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about INSP
Insiders, 180 days
-$233.3K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$61.3K
2 notices
Inspire Medical Systems insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Inspire Medical Systems, Inc. insiders sold a net $233.3K of stock across 196 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.1% of the 18,985 shares held after it.
- No other insider sold within 30 days.
Insider activity: See Remarks Kelly Jason P sold about $57.3K of INSP on Aug 7, 2026.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on May 14, 2026.
- The trade is 9.7% of the 27,165 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: See Remarks Rondoni John sold about $114.3K of INSP on May 15, 2026; 1 other insider sold within 30 days.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Jan 9, 2026.
- The trade is 2.3% of the 29,806 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: See Remarks Rondoni John sold about $30.1K of INSP on May 14, 2026; 1 other insider sold within 30 days.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 2, 2025.
- The trade is 2.5% of the 27,712 shares held after it.
- 1 other insider sold within 30 days.
Insider activity: Director mcCormick Shawn sold about $31.5K of INSP on May 8, 2026; 1 other insider sold within 30 days.Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on May 19, 2025.
- The trade is 0.8% of the 13,797 shares held after it.
- No other insider sold within 30 days.
Insider activity: See Remarks Rondoni John sold about $10.9K of INSP on Jan 9, 2026.196 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$233.3K over 180 days
-$57.3K over 90 days
below 52% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+13.6% year over year
more than 57% of Medical Devices
Margin
15.9% net margin
more than 89% of Medical Devices
Buybacks
$175.0M repurchased, FY to 2025-12-31
more than 71% of Medical Devices
Short interest
18.0% of the float short (float per yahoo 2026-10-26) · 4.6 days to cover · settled 2026-09-30
more than 96% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch INSP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-12.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INSP: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in INSP
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INSP planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JOHN RONDONI
Filed 2026-08-24
$4.0K
JASON P KELLY
Filed 2026-08-07
$57.3K
Executive pay vs shareholder return · Timothy P. Herbert
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.5M
$876.4K
$2.2M
+174%
-1%
2022
$5.7M
$8.4M
$2.1M
+239%
+5%
2021
$1.3M
$10.6M
$1.1M
+210%
+37%
2020
$4.9M
$21.7M
$2.5M
+153%
+33%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $233.3K sold by insiders over 180 days, $61.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
INSP financials
Revenue growth
+13.6%
XBRL, annual
Net margin
15.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$898.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM INSP
| FY Dec 2025 | $912.0M |
| FY Dec 2024 | $802.8M |
| FY Dec 2023 | $624.8M |
| FY Dec 2022 | $407.9M |
| FY Dec 2021 | $233.4M |
| Jun 2026 | $200.6M |
| Mar 2026 | $204.6M |
| Dec 2025 | $269.1M |
| Sep 2025 | $224.5M |
| Jun 2025 | $217.1M |
| Mar 2025 | $201.3M |
| Dec 2024 | $239.7M |
| Sep 2024 | $203.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM INSP
| FY Dec 2025 | +15.9% |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | -3.4% |
| FY Dec 2022 | -11.0% |
| FY Dec 2021 | -18.0% |
| Jun 2026 | +0.2% |
| Mar 2026 | -5.5% |
| Dec 2025 | +50.6% |
| Sep 2025 | +4.4% |
| Jun 2025 | -1.7% |
| Mar 2025 | +1.5% |
| Dec 2024 | +14.7% |
| Sep 2024 | +9.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$117.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM INSP
| FY Dec 2025 | $78.5M |
| FY Dec 2024 | $91.1M |
| FY Dec 2023 | $1.0M |
| FY Dec 2022 | $2.5M |
| FY Dec 2021 | -$24.8M |
| Jun 2026 | $14.1M |
| Mar 2026 | $3.1M |
| Dec 2025 | $41.8M |
| Sep 2025 | $58.1M |
| Jun 2025 | -$6.3M |
| Mar 2025 | -$15.1M |
| Dec 2024 | $62.2M |
| Sep 2024 | $44.3M |
At each fiscal year end
Single quarter
Debt to equity
0.03x
long-term debt only, 2022-06-30 (48 months older than the period end); equity 2026-06-30
Debt to equity INSP
| FY Dec 2025 | 0.03x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.04x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 0.11x |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.03x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
7.34x
TTM operating cash flow over long-term debt only, 2022-06-30 (48 months older than the period end)
Cash flow to debt INSP
| FY Dec 2025 | 5.47x |
| FY Dec 2024 | 6.09x |
| FY Dec 2023 | 1.15x |
| FY Dec 2022 | 0.54x |
| FY Dec 2021 | -0.82x |
| Jun 2026 | 7.34x |
| Mar 2026 | 6.38x |
| Dec 2025 | 5.47x |
| Sep 2025 | 6.25x |
| Jun 2025 | 5.49x |
| Mar 2025 | 5.36x |
| Dec 2024 | 6.09x |
| Sep 2024 | 3.66x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+18.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity INSP
| FY Dec 2025 | +19.8% |
| FY Dec 2024 | +8.5% |
| FY Dec 2023 | -4.0% |
| FY Dec 2022 | -12.4% |
| FY Dec 2021 | -18.3% |
| Jun 2026 | +18.0% |
| Mar 2026 | +18.4% |
| Dec 2025 | +19.8% |
| Sep 2025 | +6.5% |
| Jun 2025 | +8.1% |
| Mar 2025 | +10.9% |
| Dec 2024 | +8.5% |
| Sep 2024 | +5.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+15.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets INSP
| FY Dec 2025 | +17.0% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | -3.4% |
| FY Dec 2022 | -10.4% |
| FY Dec 2021 | -14.6% |
| Jun 2026 | +15.6% |
| Mar 2026 | +16.0% |
| Dec 2025 | +17.0% |
| Sep 2025 | +5.6% |
| Jun 2025 | +6.9% |
| Mar 2025 | +9.4% |
| Dec 2024 | +7.2% |
| Sep 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -95%, not meaningful
Return on invested capital INSP
| FY Dec 2025 | n/a |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +5.5% |
| Jun 2025 | +7.0% |
| Mar 2025 | +8.9% |
| Dec 2024 | +6.8% |
| Sep 2024 | +3.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+6.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed INSP
| FY Dec 2025 | +6.7% |
| FY Dec 2024 | +5.5% |
| FY Dec 2023 | -7.3% |
| FY Dec 2022 | -12.6% |
| FY Dec 2021 | -15.5% |
| Jun 2026 | +6.9% |
| Mar 2026 | +6.9% |
| Dec 2025 | +6.7% |
| Sep 2025 | +5.2% |
| Jun 2025 | +6.0% |
| Mar 2025 | +7.8% |
| Dec 2024 | +5.5% |
| Sep 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
15.66x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing INSP
| FY Dec 2025 | 18.82x |
| FY Dec 2024 | 107.16x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 9.83x |
| Mar 2026 | 11.70x |
| Dec 2025 | 18.82x |
| Sep 2025 | 50.48x |
| Jun 2025 | 75.01x |
| Mar 2025 | 73.40x |
| Dec 2024 | 107.16x |
| Sep 2024 | 193.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.9B
market value at close 2026-10-23 on 2026-07-30 shares, plus long-term debt only, 2022-06-30 (48 months older than the period end), minus cash 2026-06-30
Enterprise value INSP
| FY Dec 2025 | $2.6B |
| FY Dec 2024 | $5.4B |
| FY Dec 2023 | $5.8B |
| FY Dec 2022 | $6.9B |
| FY Dec 2021 | $6.1B |
| Jun 2026 | $1.2B |
| Mar 2026 | $1.4B |
| Dec 2025 | $2.6B |
| Sep 2025 | $2.1B |
| Jun 2025 | $3.7B |
| Mar 2025 | $4.7B |
| Dec 2024 | $5.4B |
| Sep 2024 | $6.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield INSP
| FY Dec 2025 | +2.9% |
| FY Dec 2024 | +1.6% |
| FY Dec 2023 | +0.0% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | -0.4% |
| Jun 2026 | +9.1% |
| Mar 2026 | +6.6% |
| Dec 2025 | +2.9% |
| Sep 2025 | +4.5% |
| Jun 2025 | +2.2% |
| Mar 2025 | +1.7% |
| Dec 2024 | +1.6% |
| Sep 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.10x
P/E over trailing EPS growth of 162%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing INSP
| FY Dec 2025 | 0.10x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.11x |
| Dec 2025 | 0.10x |
| Sep 2025 | 1.45x |
| Jun 2025 | 0.10x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $912.0M | $802.8M | $624.8M | $407.9M |
| Gross profit | $778.8M | $679.8M | $528.2M | $341.7M |
| Operating income | $51.0M | $36.1M | -$40.3M | -$47.6M |
| Net income | $145.4M | $53.5M | -$21.2M | -$44.9M |
| EPS (diluted) | 4.89 | 1.75 | -0.72 | -1.60 |
| Operating cash flow | $117.0M | $130.2M | $24.7M | $11.6M |
| Cash | $104.8M | $150.2M | $185.5M | $441.6M |
| Buybacks | $175.0M | $0 | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
INSP Stock Sonar score 5/7 axes
Find similar shapesCompareINSP ranks highest on financial health (89th percentile) and profitability (87th), and lowest on risk and compliance (22nd), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
INSP filings, in plain words
Are Inspire Medical Systems insiders buying or selling INSP?
In the 180 days to 2026-10-27, Inspire Medical Systems insiders were net sellers, a net $233.3K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of INSP?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $61.3K of stock; the latest, by JOHN RONDONI, was filed 2026-08-24.
Read the full summary
In the 180 days to 2026-10-27, Inspire Medical Systems insiders were net sellers of INSP, a net $233.3K across purchases and sales reported on Form 4 by 3 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $61.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
